Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study
Fatemeh Saberi Hosnijeh(Utrecht University), Mark‐David Levin(Albert Schweitzer Hospital), Jeanette K. Doorduijn(Erasmus MC Cancer Institute), Martine E.D. Chamuleau(Hovon), Sanne H. Tonino(Amsterdam UMC Location University of Amsterdam), M Schaafsma(Medisch Spectrum Twente), Michel van Gelder(Maastricht University), G. Doreen te Raa(Ziekenhuis Gelderse Vallei), Mels Hoogendoorn(Medisch Centrum Leeuwarden), Ward Posthuma(Leiden University Medical Center), Mar Bellido(University Medical Center Groningen), J. Martijn Kerst(The Netherlands Cancer Institute), Sabina Kersting(Haga Hospital), Erik W.A. Marijt(Radboud University Nijmegen), Arnon P. Kater(Amsterdam University Medical Centers), Reinier Raymakers(University Medical Center Utrecht), Anton W. Langerak(Erasmus MC), Fransien de Boer(Ikazia Ziekenhuis), Marinus H. J. van Oers(Academic Medical Center), Johan A. Dobber(Amsterdam University Medical Centers), Harry R. Koene(St. Antonius Ziekenhuis), Lina van der Straten(Erasmus MC)
Cited by 8
Related Papers
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630